Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 5, 2014

Ebola Serum Turns Out to Be an Antibody Cocktail

Ebola Serum Turns Out to Be an Antibody Cocktail

Source: Dream Designs/Shutterstock Photos

  • The “secret serum” being used to treat the two Americans infected with Ebola virus is a humanized, three-monoclonal-antibody experimental cocktail provided by Mapp Biopharmaceutical, a small San Diego-based biotech company. Known as ZMapp™, the product is the result of a collaboration between Mapp, LeafBio, Toronto-based Defyrus, the U.S. government, and the Public Health Agency of Canada.

    Up until now ZMapp had only been used to treat monkeys (successfully) and has not yet entered human clinical trials. Due to the deadly nature of Ebola, the decision was made to administer ZMapp to Kent Brantly, M.D., and Nancy Writebol, who are now being treated at Emory University Hospital after being flown back to the U.S. from Liberia where they contracted the disease. Both patients reportedly are responding positively.

    ZMapp is composed of components of Mapp Biopharmaceutical’s MB-003 monoclonal and two monoclonals from Defyrus’ ZMAb program. The antibodies are being produced under an existing manufacturing collaboration with Kentucky Bioprocessing. Using a fully automated production system that operates in accordance with GMP procedures, the antibodies are manufactured in a tobacco plant, Nicotiana.

    “ZMapp was first identified as a drug candidate in January 2014,” according to Mapp Biopharmaceutical. “As such, very little of the drug is currently available. Any decision to use an experimental drug in a patient would be a decision made by the treating physician under the regulatory guidelines of the FDA. Mapp and its partners are cooperating with appropriate government agencies to increase production as quickly as possible.”

    Do you think that Ebola victims should be barred from entering the U.S. or any other developed country even if that country has the proper and safe types of medical procedures in place and the facilities to treat the disease?



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »